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Abstract
Background: Membranous nephropathy is an important glomerular disease characterized by podocyte injury and
proteinuria, but no metabolomics research was reported as yet. Here, we performed a parallel metabolomics study,
based on human urine and serum, to comprehensively profile systematic metabolic variations, identify differential
metabolites, and understand the pathogenic mechanism of membranous nephropathy.
Results: There were obvious metabolic distinctions between the membranous nephropathy patients with urine
protein lower than 3.5 g/24 h (LUPM) and those higher than 3.5 g/24 h (HUPM) by Partial Least Squares
Discriminant Analysis (PLS-DA) model analysis. In total, 26 urine metabolites and 9 serum metabolites were
identified to account for such differences, and the majority of metabolites were significantly increased in HUPM
patients for both urines and serums. Combining the results of urine with serum, all differential metabolites were
classified to 5 classes. This classification helps globally probe the systematic metabolic alterations before and after
blood flowing through kidney. Citric acid and 4 amino acids were markedly increased only in the serum samples
of HUPM patients, implying more impaired filtration function of kidneys of HUPM patients than LUPM patients. The
dicarboxylic acids, phenolic acids, and cholesterol were significantly elevated only in urines of HUPM patients,
suggesting more severe oxidative attacks than LUPM patients.
Conclusions: Parallel metabolomics of urine and serum revealed the systematic metabolic variations associated
with LUPM and HUPM patients, where HUPM patients suffered more severe injury of kidney function and oxidative
stresses than LUPM patients. This research exhibited a promising application of parallel metabolomics in renal
diseases.
Background
Membranous nephropathy (MN) is an important glo-
merular disease characterized by podocyte injury and
proteinuria. Although the definite pathogenic mechan-
isms of MN has not yet been entirely clarified, it is
widely accepted that MN involves the in situ formation
of subepithelial immune complex deposits and subse-
quent complement activation leading to podocyte injury
and diffuse thickening of the glomerular basement
membrane, based on experimental animal models and
human studies [1-3]. The diagnosis and treatment of
MN patients are presently based mainly on clinical man-
ifestations, urinary protein excretion levels, and renal
biopsy. Renal biopsy, though providing specific diagnosis
currently, is an invasive procedure with considerably sig-
nificant complications, particularly in patients with
bleeding tendency or skin infection on the flank. Thus,
a renal biopsy may be contraindicated for certain high
risk patients, and was often refused by early patients. At
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the stage of MN, the function of glomerular filtration
can be kept in a normal range. Routine clinical chemical
measures of renal function based on blood, such as
serum creatinine, serum uric acid, albumin, and total
protein, are insensitive and laggard for early diagnosis.
They elevated significantly only after substantial kidney
injury occurs, generally after a loss of two third or
greater of nephron functional capacity [4]. However, the
metabolites that are overproduced during MN progres-
sion will enter urine space and be secreted into final
urine. For this reason, urine possibly is an ideal source
of test materials to noninvasively characterize the activ-
ity of kidney.
Metabolomics, an important constituent of systems
biology, aims to simultaneously measure as many meta-
bolites as possible in a given biological system in order
to acquire an overview of metabolic status and global
biochemical events associated with a cellular or biologi-
cal system [5]. It is well known that the minor alteration
at the level of gene or protein expression usually leads
to significant change in metabolite level. Combining a
robust instrumental analysis with whole metabolite
information and multivariate statistical analysis, such as
principal component analysis (PCA) and partial least
squares discriminant analysis (PLS-DA), metabolomics
has been a considerably intensive means for comprehen-
sively evaluating toxicity of drugs or xenobiotics [6,7],
early diagnosis and identifying potential biomarkers
[8,9], and elucidating biological pathways [10]. Mass
spectrometry (MS) and nuclear magnetic resonance
(NMR) spectroscopy are major analytical tools for meta-
bolomics. MS coupled with advanced chromatographic
separation instruments, such as gas chromatography
(GC) or liquid chromatography (LC), has become a
powerful metabolomics tool, with a wide dynamic range
and reproducible quantitative performance, for the mea-
surement of complex biological samples. GC/MS is a
robust analytical platform for quantification with better
sensitivity and resolution than the commonly used
NMR approach and better reliability in structure identi-
fication of candidate biomarkers than LC/MS [11]. It
has been widely applied in metabolomics research of
biofluids, feces, and tissue samples [6,12-14]. Nowadays,
metabolomics has been successfully used in the fields of
physiology, diagnostics, functional genomics, pharmacol-
ogy, toxicology, and nutrition. Furthermore, simple and
non-invasive sample collection techniques, fast instru-
mental analysis, and meaningful diagnostic information
enable urine to be a considerably suitable biofluid for
metabolomics analysis in personalized medicine such as
the recent application in personalized neonatal medicine
[15].
Urine-based metabolomics has been applied in the
researches of early detection and renal toxicity [6,9],
diagnosis, biomarker identification, and pathogenic path-
way of kidney cancer [8,16]. To our knowledge, there is
no research work published about MN based on meta-
bolomics. In omics field, there is only a paper reported
the changes of urinary proteome profile using a MN
animal model [17]. In the present study, we adopted a
GC/MS-based metabolomics approach, based on clinical
urine and serum samples, to systematically evaluate the
metabolic alterations and understand the differential
pathological characteristics between the MN patients
with urine protein lower than 3.5 g/24 h and those with
urine protein higher than 3.5 g/24 h. Ongoing work in
our lab is directed to further study of such disease at a
larger sample scale and validate the potential biomarkers
for the researches of clinical diagnosis and pathological
mechanism.
Results
Histopathology and clinical chemistry
The diagnosis and grading of MN patients were per-
formed according to clinical chemical parameters and
renal biopsy. The patients were clinically classified to
Low Urine Protein MN group (LUPM, urine protein <
3.5 g/24 h) and High Urine Protein MN group (HUPM,
urine protein > 3.5 g/24 h). According to the detailed
PCA analysis in the next section, 3 samples with serum
creatinine higher than 110 μmol/l but urine protein
lower than 3.5 g/24 h were found to be outliers, and
were excluded from final statistics of clinically chemical
parameters. Table 1 lists the clinical parameters.
Although the average urine creatinine level of HUPM
group was higher than that of LUPM group, there was
no statistical difference between them. It was worth not-
ing that the serum creatinine of HUPM group was sig-
nificantly higher than that of LUPM group, suggesting
the different glomerular filtrate rate and renal function
between the two groups of MN patients. Obviously, the
serum creatinine clearance by kidneys of HUPM
patients was weaker than LUPM patients, but the creati-
nine values of both two groups were still within the
Table 1 Clinically chemical analysis of membranous
nephropathy











Urine protein (g/24 h) 1.42 ± 1.07 5.17 ± 1.70 < 0.001
Urine creatinine (mmol/24 h) 8.91 ± 6.62 11.59 ± 3.08 0.211
Serum creatinine (Scr, μmol/l) 58.89 ± 15.0 85.4 ± 31.8 0.039
Serum total protein (g/l) 60.2 ± 12.6 45.9 ± 12.6 0.023
Serum albumin (g/l) 34.0 ± 8.7 22.6 ± 7.5 0.006
Blood urea nitrogen (BUN,
mmol/l)
4.7 ± 1.8 6.4 ± 2.5 0.115
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normal range. In general, the glomerular basement
membrane with normal function is negatively charged in
the body, which prevents the filtration of the negatively
charged proteins such as albumin to the urine. In con-
trast to the LUPM group, the markedly reduced serum
albumin and total protein in HUPM group possibly
reflected the increased damage of glomerular basement
membrane.
Urinary metabolomics analysis
Trimethylsilyl derivatization was applied in sample pre-
paration prior to GC/MS analysis. This derivatization
can efficiently improve GC/MS analysis of the com-
pounds which contain carboxylic, amino, or hydroxyl
group, such as fatty acids, amino acids, amines, hydroxyl
acids, carbohydrates, and phenolic acids. The represen-
tative urinary GC/MS total ion current (TIC) chromato-
grams of the LUPM and the HUPM patients were
displayed in Figure 1A and 1B, respectively. A total of
512 chromatographic peaks were resolved from over
80% of samples after the exclusion of known internal
standard and artifact peaks. In order to obtain more
reliable outcomes at the level of population, multivariate
statistical analysis, such as PCA and PLS-DA, was per-
formed on the preprocessed GC/MS data matrices. PCA
was initially performed on the normalized peak areas
obtained from all the samples to evaluate the quality of
sample analysis and view the holistic distribution, clus-
tering, and outlier of samples. The PCA scores plot (2
principal components, R2X = 0.269, Q2 = 0.109, Figure
1C) shows that all QC samples, prepared by pooling the
urine samples in this study, are tightly clustered in a
small area, demonstrating that current protocol is reli-
able and thereby the variance derived from metabolo-
mics analysis can be ignored at the following data
analysis [18]. Four samples were out of the Hotelling T2
95% confidence, and thus were suspected as outlier sam-
ples. After checking the clinically chemical parameters,
it was found that all of the 3 samples with serum creati-
nine higher than 110 μmol/l but urine protein lower
Figure 1 Representative urinary GC/MS total ion current (TIC) chromatograms and the scores plots of PCA and PLS-DA. (A), the
representative GC/MS TIC chromatogram of LUPM patient urine; (B), the representative GC/MS TIC chromatogram of HUPM patient urine; (C),
PCA scores plot of QC (square), LUPM (dot), and HUPM (diamond) urines with outliers, QC sample was prepared by pooling the urine samples in
this study; (D), PCA scores plots of LUPM (dot) and HUPM (diamond) urines after excluding outliers; (E), PLS-DA scores plots of LUPM (dot) and
HUPM (diamond) urines after excluding outliers.
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than 3.5 g/24 h were involved in the outliers. In addi-
tion, the outlier samples with high serum creatinine dis-
tributed in scattered space of PCA scores plot. The
three samples and another one outlier sample were
excluded at the subsequent analysis.
After removing 4 outlier samples, PCA model (2 com-
ponents, R2X = 0.229, Q2 = 0.041) was constructed
again, and the scores plot shows that no evident separa-
tion but a separation tendency indeed exists between
the LUPM group and HUPM group (Figure 1D). R2 and
Q2 values were calculated for the model to assess any
significance of differentiation and the quality of model.
The low statistical parameters showed that PCA model
was not suitable for interpreting the differences. A PLS-
DA model with 3 components was thus conducted to
reveal the differences between the two groups. The PLS-
DA model showed significantly improved model predict-
ability (Q2 = 0.657), and fairly good capability to explain
the metabolic variation between LUPM and HUPM
patients (R2Y = 0.977). Figure 1E indicates that the two
groups are evidently separated in PC1 and PC2. The
PLS-DA scores plot implied that the severity of MN
patients could be discriminated according to the urine
protein level.
The differential metabolites contributing to the meta-
bolic differences between the LUPM group and HUPM
group were further identified. Among the statistically
significant variables, 26 differential metabolites were
structurally qualified using reference compounds and
NIST library with retention indexes http://www.sisweb.
com/software/ms/nist.htm. These metabolites were sum-
marized in Table 2.
They mainly included dicarboxylic acids, hydroxyl
acids, phenolic acids, TCA cycle intermediates, sugar
alcohols, cytosine, quinolinic acid, and cholesterol. In
contrast to LUPM subjects, the majority of metabolites
were increasingly excreted in the urines of HUPM
patients. Dicarboxylic acids are generally the products of
polyunsaturated fatty acids under oxidative stress. Sugar
alcohols are commonly as the regulator of the osmotic
pressure during the formation of urine. The overproduc-
tion of this kind of metabolites in the urines of HUPM
patients indicated that the re-absorption function and
self metabolism of their kidney possibly received more
severe injury than LUPM subjects.
Metabolomics analysis of serum samples
Serum samples were simultaneously analyzed in this
study. With the consent of patients, we collected the
serum samples of a part of volunteer patients. The
representative serum GC/MS total ion current (TIC)
chromatograms of the LUPM patient and the HUPM
patient were shown in Figure 2A and 2B, respectively.
Totally, 217 chromatographic peaks were obtained from
the over 80% of samples after exclusion of known inter-
nal standard and artifact peaks. Similar to urine metabo-
lomics analysis, we first performed a PCA model to
validate the robustness of our metabolomics protocol.
After exclusion of QC samples, a new PCA model was
performed again. The PCA scores plot (Figure 2C) indi-
cates that, similar to urine, no clear profile separation
was present between the two groups of samples (2 com-
ponents, R2X = 0.366, Q2 = 0.081). The small values of
statistical parameters indicated that PCA model cannot
explain the differences between the serum samples of
LUPM and HUPM patients. Subsequently, a PLS-DA
model was conducted to reveal variations between the
two groups. The parameters (2 components, R2Y =
0.935, Q2 = 0.639) indicated that the PLS-DA model
was reliable to explain the phenotype difference between
the LUPM and HUPM patients. The PLS-DA scores
plot demonstrates that the two groups of samples are
well separated to two clusters, thus the LUPM group
was different from the HUPM group by metabolomics
analysis of serum samples (Figure 2D).
The serum metabolites contributing to such metabolo-
mics profile separation were identified. Nine serum
metabolites were annotated by the NIST library, and of
which 7 metabolites were confirmed by our reference
compounds (Table 3). The number of differential meta-
bolites from serum is obviously less than that from
urine. Similar to the urine results, cholesterol was found
significantly increased in the HUPM group. However,
unlike urine, the citric acid level of HUPM group was
significantly higher than that of LUPM group. No urin-
ary amino acids were found differentially expressed
between the LUPM and the HUPM patients, but 4
serum amino acids were significantly increased in the
HUPM patients.
Discussion
The metabolites that are massively overproduced during
the progression of membranous nephropathy and fit the
criteria of glomerular filtration, including blood and the
metabolites of kidney, will enter urine space and the
final urine. In this study, the routine clinical chemical
measures of renal function indicated that the serum
creatinine of almost all patients were kept in normal
range, suggesting that the function of glomerular filtra-
tion probably was not substantially altered, irrespective
of glomerular injury happened actually. Here, we per-
formed a parallel metabolomic study based on urine and
serum to globally profile metabolic differences and iden-
tify differential metabolites, and attempted to under-
stand the pathogenic mechanism of membranous
nephropathy based on different urine protein levels.
It is important to compare the differential metabolites
before kidney (ie. serum) and after kidney (ie. urine).
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The number of differential urinary metabolites was
markedly more than that of differential serum metabo-
lites between the patients of LUPM and HUPM. The
levels of the majority of differential metabolites were
significantly increased in HUPM patients for both urines
and serums. Figure 3 demonstrates that all differential
metabolites can be classified to 5 groups according to
their change trend in urine and serum. Cholesterol was
higher in both urine and serum of HUPM patients
(Class 1). Four amino acids were found as differential
serum metabolites with markedly increased levels in
HUPM patients, while they were not differentially
excreted in the urines (Class 2). Class 2 reflects that the
kidneys of HUPM patients possibly possessed weaker fil-
tration ability for amino acids and citric acid, and thus
suffered more severe injury than those of LUPM
patients. It was presumed that these elevated 4 amino
acids and citric acid in serum samples of HUPM
patients probably came from the metabolism of other
organs (via blood) rather than kidney, and were to some
extent prevented into urine by impaired kidney. 2-Keto-
3-methylvaleric acid and m-cresol were higher in the
serums of LUPM patients and classified to Class 3, but
their functions remain unclear. The Class 4 contains lac-
tose and cis-aconitic acid with higher secretion only in
the urines of LUPM patients. Other differential metabo-
lites increased only in urines of HUPM patients (Class
5), such as sugar alcohols, dicarboxylic acids, hydroxyl
acids, and phenolic acids, are possibly derived from the
metabolism of kidney, because there were no differences
between the serum samples of LUPM and HUPM
patients. Thus, the metabolites of Class 5 probably were
the direct outcomes of renal injury.
Four sugar alcohols (polyols) were increasingly
excreted in the urines of HUPM patients, while their
concentrations were not changed significantly in the
serum samples. Polyols are polyhydric alcohols, derived
from aldoses and ketoses by reduction with NADPH. In
this study, the serum and urine glucose levels of HUPM
patients were significantly higher than those of LUPM
Table 2 Differential urinary metabolites between HUPM and LUPM patients
No. Compounds VIP a p-Value b FDR c FC d Biochemical pathway
1 cis-Aconitic acid 1.73 9.87E-03 2.42E-02 -0.74 TCA cycle
2 Lactose 1.55 2.23E-02 3.54E-02 -0.45 Galactose metabolism
3 Erythritol 1.72 9.99E-03 2.25E-02 0.41 Polyol metabolism
4 Xylitol 1.39 4.27E-02 4.80E-02 0.30 Pentose and glucuronate interconversions
5 Galactitol 1.38 4.86E-02 4.86E-02 0.62 Galactose metabolism
6 Inositol 1.73 9.63E-03 2.60E-02 1.00 Galactose metabolism
7 Glyceric acid 1.52 2.54E-02 3.43E-02 0.69 Glyoxylate and dicarboxylate metabolism
8 2,4-Dihydroxybutyric acid 1.74 9.20E-03 2.76E-02 0.44 Fatty acid metabolism
9 Threonic acid 2.17 7.40E-04 6.66E-03 0.35 Ascorbate and aldarate metabolism
10 2-Deoxyribonic acid 1.58 1.97E-02 3.32E-02 0.39
11 2-Ketogluconic acid 1.71 1.07E-02 2.22E-02 0.41
12 Glutaric acid 1.66 1.37E-02 2.47E-02 0.48 Fatty acid metabolism, Lysine degradation
13 3-Methylglutaric acid 1.74 9.12E-03 3.08E-02 0.48 Leucine metabolism
14 Adipic acid 2.17 6.97E-04 9.41E-03 0.58 Fatty acid metabolism
15 2-Hydroxyglutaric acid 1.94 3.13E-03 1.41E-02 0.40 Fatty acid metabolism
16 Suberic acid 1.70 1.30E-02 2.51E-02 0.54 Fatty acid metabolism
17 3-Hydroxysebacic acid 1.56 2.36E-02 3.54E-02 0.80 Fatty acid metabolism
18 Mandelic acid 1.44 3.47E-02 4.46E-02 0.50 Aminobenzoate degradation
19 4-Hydroxyphenylacetic acid 1.41 3.86E-02 4.53E-02 0.37 Phenylalanine and tyrosine metabolism
20 Vanillic acid 1.36 4.70E-02 4.88E-02 0.25 Gut microflora metabolism
21 3,4-Dihydroxybenzoic acid 1.42 3.83E-02 4.70E-02 0.69 phenylalanine, tyrosine and tryptophan biosynthesis
22 4-Hydroxyphenyllactic acid 1.52 2.53E-02 3.60E-02 0.49 Phenylalanine and tyrosine metabolism
23 Vanillactic acid 2.04 1.66E-03 1.12E-02 1.15 Gut microflora metabolism
24 Cytosine 1.91 3.71E-03 1.43E-02 0.81 Pyrimidine metabolism
25 Quinolinic acid 2.31 2.53E-04 6.83E-03 0.61 Nicotinate and nicotinamide metabolism
26 Cholesterol 1.97 2.70E-03 1.46E-02 1.51 Steroid biosynthesis
a Variable importance in the projection (VIP) was obtained from PLS-DA model with value higher than 1.0;
b The p-value calculated from two-tailed Student’s t test;
c FDR adjusted p value from two-tailed Student’s t test;
d Fold change was calculated as binary logarithm of average mass response (normalized peak area) ratio between HUPM and LUPM patients, where the positive
value means that the average mass response of the metabolite in the HUPM group is larger than that in the LUPM group.
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subjects (no statistical significance for urinary glucose, p
= 0.058), suggesting that these polyols possibly came
from the elevated glucose. Recent research proved that
erythritol was an excellent antioxidant [19], and attenu-
ated the diabetic oxidative stress [20].
The increasing evidence shows that oxidative stress
formed in podocyte response to the membrane attack
complex C5b-9 induced injury is an important outcome.
The attack of C5b-9 on podocytes induces production
of reactive oxygen species (ROS), which initiate lipid
peroxidation and subsequent degradation of glomerular
basement membrane collagen IV, leading to develop-
ment of proteinuria [21]. In this research, the majority
of metabolites in Class 1 and 5 were presumed to be
closely related to the increased oxidative stress. Accord-
ing to previous knowledge, we proposed a metabolic
network associating with the increased oxidative stress
during the developing of membranous nephropathy
(Figure 4).
In this study, a series of dicarboxylic acids and corre-
sponding hydroxyl metabolites, such as adipic acid,
suberic acid, and 3-hydroxysebacic acid, were excessively
Figure 2 Representative serum GC/MS TIC chromatograms and the scores plots of PCA and PLS-DA. (A), the representative serum GC/MS
TIC chromatogram of LUPM patient; (B), the representative serum GC/MS TIC chromatogram of HUPM patient; (C), PCA scores plots of LUPM
(dot) and HUPM serums (diamond); (D), PLS-DA scores plots of LUPM (dot) and HUPM serums (diamond).
Table 3 Differential serum metabolites between HUPM and LUPM patients
No. Compound VIP a p-Value b FDR c FC d Biochemistry pathway
1 m-Cresol 1.93 1.45E-02 2.61E-02 -1.66 Gut microflora metabolism
2 2-Keto-3-methylvaleric acid 2.31 4.47E-03 1.34E-02 -0.58 Fatty acid metabolism
3 L-Asparagine # 2.34 1.40E-03 6.30E-03 0.40 Alanine, aspartate and glutamate metabolism
4 L-Serine # 2.46 1.04E-03 9.36E-03 0.79 Glycine, serine and threonine metabolism
5 L-Threonine # 1.90 1.47E-02 2.21E-02 0.56 Glycine, serine and threonine metabolism
6 Pyroglutamic acid # 1.63 3.60E-02 4.05E-02 0.27 Glutathione metabolism
7 Citric acid # 1.96 1.35E-02 3.04E-02 0.85 TCA cycle
8 Glucose # 1.53 4.80E-02 4.80E-02 0.44 Glycolysis, Pentose phosphate pathway, Galactose metabolism
9 Cholesterol # 1.82 2.07E-02 2.66E-02 0.41 Steroid biosynthesis
a Variable importance in the projection (VIP) was obtained from PLS-DA model with value higher than 1.0;
b The p-value was calculated from Student’s t test;
c FDR adjusted p value from two-tailed Student’s t test;
d Fold change was calculated as binary logarithm of average mass response (normalized peak area) ratio between HUPM and LUPM patients, where the positive
value means that the average mass response of the metabolite in the HUPM group is larger than that in the LUPM group;
# The metabolite was structurally confirmed by available reference compound.
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Figure 3 Trend map of differential metabolites in urine (blue) and serum (red) between LUPM and HUPM patients. Horizontal axis
represents metabolites, and vertical axis represents fold change between HUPM and LUPM (HUPM/LUPM). The bar above zero axis means the
concentration of this metabolite is higher in HUPM patients than in LUPM patients. The bar below zero axis means the concentration of this
metabolite is higher in LUPM patients than in HUPM patients. If the metabolite was not significantly changed between LUPM and HUPM
patients, it was blank. Fold change was calculated as binary logarithm of average mass response (normalized peak area) ratio between HUPM
and LUPM patients, where the positive value means that the average mass response of the metabolite in the HUPM group is larger than that in
the LUPM group. All of these differential metabolites were classified to 5 groups according to their change trend in urine and serum.
Figure 4 Proposed metabolic network associating with increased oxidative stress during the developing of membranous
nephropathy. C5b-9 attack, the attack from membranous protein complex C5b-9 on podocyte; ROS, reactive oxygen species; L, Low urine
protein membranous nephropathy; H, High urine protein membranous nephropathy; S, serum; U, urine; Red box means that the metabolite in
urine or serum of “H” group was increased significantly than “L” group.
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excreted in the urines of HUPM patients, compared
with LUP patients. Bergseth et al [22] found that urinary
dicarboxylic acids might to a significant extent be
formed in the kidneys themselves. Glutaric acid, a pro-
duct of lysine degradation, can induce oxidative stress in
brain of young rat [23]. Under pathological status, free
or esterified cis-polyunsaturated fatty acids generated
saturated short- (ie. adipic acid) and medium-chain
length dicarboxylic acids (ie. suberic acid) due to peroxi-
somal disorder by oxidative attack [24]. The elevated
urinary (hydroxyl)dicarboxylic acids in HUPM patients
possibly reflected an more severe oxidative stress than
LUPM patients in this study.
Threonic acid is another one metabolite of interest.
The formation of this metabolite is closely related to the
deficiency or degradation of ascorbic acid, a potent
water-soluble antioxidant that readily scavenges free
radicals such as molecular oxygen, superoxide, and
hydroxyl radical [25]. Threonic acid is related to the
protein collagen, but its function in nephropathy
hitherto was still not reported. The higher level of urin-
ary threonic acid in HUPM patients than LUPM
patients indirectly indicated the significantly strength-
ened oxidative stress in HUPM patients. It is known
that ascorbic acid helps decrease cholesterol. The
increased urinary and serum cholesterol levels in the
HUPM patients further proved the deficiency of ascorbic
acid and hence the increased oxidative stress.
Previous proteomics research based on a rat MN
model found that aldehyde dehydrogenase, which is cap-
able of converting 9-cis and all-trans retinal to corre-
sponding retinoic acid with high efficiency, was
decreased [17]. Its function has been suggested to
involve in oxidative pathway [26]. It is known that
HUPM patients clinically are more severe than LUPM
patients. Metabolomics analysis in this research proved
the more strengthened oxidative stress, mainly in kid-
ney, during the pathogenesis and progression of HUPM
patients. Currently, studies that used antioxidants and
oxygen radical scavengers have demonstrated beneficial
effects in animal model and human MN treatments
[27,28].
A lot of phenolic acids were increasingly excreted in
the urines of HUPM patients. They are the metabolites
of phenylalanine and tyrosine metabolism and usually
serve as antioxidants [29,30]. In contrast to LUPM
patients, the increased 3,4-dihydroxybenzoic acid, 4-
hydroxyphenylacetic acid, vanillic acid, and vanillactic
acid in the urines of HUPM patients suggested that
more antioxidants were possibly produced and trans-
ferred into glomerulus to defense the increasing oxida-
tive stress during pathological progression, and
thereafter excreted massively in urines. In this study,
however, we did not know whether these phenolic acids
were primarily formed in kidney or in other organs,
because no differences were found between the serum
samples of the two groups of patients.
A phenolic acid of special interest is 4-hydroxyphenyl-
lactic acid, which was increasingly excreted in the urines
of HUPM patients. It is a carcinogenic metabolite of the
disorder of tyrosine metabolism, and will be increasingly
produced in patients with deficiency of p-hydroxyphe-
nylpyruvate oxidase. It was demonstrated to decrease
considerably ascorbic acid concentration in mouse
organ and blood [31]. It can impair the function of kid-
ney tubules. Such different concentration likely sug-
gested the more serious kidney injury happened in
HUPM patients.
Quinolinic acid is an important metabolite which lies
upstream of NAD+ and NADP+. Increased quinolinic
acid in the kidneys of HUPM patients provided the pre-
cursor of NADPH for the biosysnthesis of polyols, dicar-
boxylic acids, and pyrimidine metabolism. Quinolinic
acid could reduce antioxidant defenses in rat brain
[32,33]. The increased quinolinic acid in HUPM patients
possibly reduced the effects of antioxidants. One recent
research suggested a link between quinolinic acid and
kidney disease with increased proliferation when kidney
mesangial cells were exposed to this compound in vitro
[34]. Kim et al [8] performed a urine metabolomics ana-
lysis to find the correlation between kidney cancer and
increased quinolinic acid. Based on previous knowledge
and our results, we presumed that oxidative stress was
one of the vital features in the developing of MN.
Conclusions
Parallel metabolomics of urine and serum based on GC/
MS platform is an appropriate approach for revealing
the systematic alteration associated with diverse renal
diseases, such as membranous nephropathy in current
research. In this case, there were obvious metabolic dis-
tinctions between the patients with urine protein lower
than 3.5 g/24 h (LUPM) and those higher than 3.5 g/24
h (HUPM) according to PLS-DA model analysis. In
total, 26 urine metabolites and 9 serum metabolites
were identified to account for such differences. The
majority of differential metabolites was significantly
increased in HUPM patients for both urines and serums.
Combining the differential urine with serum metabo-
lites, all metabolites were classified to 5 classes. The
markedly increased metabolites (4 amino acids and citric
acid) only in the serum samples of HUPM patients
implied more severe injury of renal filtration function
than LUPM patients. The significantly increased excre-
tion of dicarboxylic acids, threonic acid, quinolinic acid,
cholesterol, and phenolic acids in urines of HUPM
patients suggested more severe oxidative stresses than
LUPM patients. These results prompted us that the
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severity of membranous nephropathy was associated
with oxidative stress. In summary, the parallel metabolo-
mics of urine and serum is a promising approach reveal-
ing systematic metabolic variations associated with renal
diseases. The urinary marker metabolites correlated with
oxidative stress also showed a prospective application in
early diagnosis of renal diseases.
Methods
Experimental participants
The experimental design involved urine samples from
14 MN patients with urine protein lower than 3.5 g/24
h (Low Urine Protein MN group, LUPM), and 15 MN
patients with urine protein higher than 3.5 g/24 h (High
Urine Protein MN group, HUPM). The other 3 MN
patients with serum creatinine higher than 110 μmol/l
but urine protein lower than 3.5 g/24 h generally have
the similar clinical manifest and were classified to the
HUPM group, thus 18 HUPM subjects were involved at
the initial PCA analysis. All MN subjects were recruited
from the outpatients of the Longhua Hospital affiliated
to Shanghai University of Traditional Chinese Medicine
(Shanghai, China). They were diagnosed definitely and
graded by clinical manifestations, urinary protein excre-
tion levels, serum creatinine, and percutaneous renal
biopsy. After collecting, urine samples were immediately
frozen, and serum samples were separated from vein
blood within 1 h after blood draw. All urine and serum
samples were stored at -80°C prior to sample prepara-
tion and GC/MS analysis. This experiment was
approved by Research Ethics Committee of Longhua
Hospital, and written informed consent was obtained
from all participants.
Chemicals
N, O-bis(Trimethylsilyl)trifluoroacetamide (BSTFA) with
1% trimethylchlorosilane (TMCS) and methoxylamine
were the products of Supelco (Bellefonte, PA). High-per-
formance liquid chromatography grade ethanol and hep-
tane was purchased from CNW Technologies GmbH
(Düsseldorf, Germany). All standard compounds, urease
(Type III, from Canavalia ensiformis), anhydrous pyri-
dine, and alkane standard mixture (C10-C40) were com-
mercially obtained from Sigma-Aldrich.
Sample preparation and derivatization
Urine samples were thawed in ice-water and short-time
vortexed at room temperature. Fifty microliters of urine
was incubated with 20 μl of 2000 U/ml urease at 37°C
for 60 min. Then, 420 μl of ice-cold ethanol was added
into the reaction solution. The mixture was vortexed for
30 s, placed at 4°C for 20 min, and subsequently centri-
fuged at 20 000 g at 4°C for 10 min. A quality control
(QC) sample was prepared by pooling the urine samples
in this study. A 392 μl of supernatant in glass vial was
dried under gentle nitrogen stream, and subsequently,
50 μl of 15 mg/ml methoxylamine in pyridine was
added. The resultant mixture was vortex-mixed vigor-
ously for 30s and incubated at 37°C for 90 min to inhi-
bit the cyclization of reducing sugars and the
decarboxylation of a-keto acids. Fifty microliters of
BSTFA (with 1% TMCS) were added into the mixture
and derivatized at 70°C for 60 min, and subsequently a
20 μl of 200 μg/ml nonadecanoic acid methylester dis-
solved in heptane was added into the cooled derivatives.
The final mixture was vortexed for 30s and placed in
sample plate for 30 min prior to injection. At the same
time, a control derivatization sample (urine was replaced
by deionized water) was prepared in order to remove
the background noise produced during sample prepara-
tion and GC/MS analysis.
Serum samples were thawed in ice-water and short-
time vortexed at room temperature. Twenty microliters
of serum was added into 60 μl of methanol-chloroform
(3:1). The mixture was vortexed for 30 s, and placed in
ice-water for 15 min prior to centrifugation at 20 000 g
at 4°C for 10 min. A 64 μl of supernatant was trans-
ferred to a glass vial and dried under gentle nitrogen
stream. The following steps are the same as the protocol
of urine sample preparation.
GC/MS analysis
The derivatized urine samples were analyzed by an Agi-
lent 7890A gas chromatography system coupled to an
Agilent 5975C MSD system with Triple-Axis Detector
(Agilent, CA) as described in published literature except
that the solvent delay time was set to 6.5 min [35].
Data extraction and preprocessing
The extraction, alignment, deconvolution, and further
processing of raw GC/MS data were principally referred
to the previous published protocol [35]. The different
parameters were time window 390-2940 s and mass
window 70-600 m/z.
Multivariate statistical analysis
The peak table (named matrix X) obtained from the sec-
tion “Data extraction and Preprocessing” was imported
to a commercial software Simca-P 11.0 (Umetrics,
Umeå, Sweden), where multivariate statistical analysis,
such as PCA and PLS-DA, was performed. All data were
mean-centered and unit variance (UV)-scaled prior to
multivariate statistical analysis. The PCA was used to
evaluate the quality of sample analysis and holistically
observe the general clustering and trends among all
samples, while the PLS-DA model was used to amplify
variations with a supervised means and identify the dif-
ferential metabolites between two groups. The
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Hotelling’s T2 region, shown as an ellipse in score plots
of the models, defines the 95% confidence interval of
the modeled variation. The quality of the models is
described by the R2X or R2Y and Q2 values. R2X or R2Y
is defined as the proportion of variance in the data
explained by the models and indicates goodness of fit.
Q2 is defined as the proportion of variance in the data
predictable by the model and indicates predictability,
calculated by cross-validation procedure [36]. A default
7-round cross-validation in Simca-P was performed
throughout to determine the optimal number of princi-
pal components and avoid model over-fitting. The
values of R2X, R2Y, and Q2 were used as indicatives to
assess the robustness of a pattern recognition model.
The differential metabolites were determined based on
the combination of a statistically significant threshold of
Variable Influence on Projection (VIP) values obtained
from PLS-DA model and FDR adjusted p values from
two-tailed Student’s t test on the normalized peak areas,
where the metabolites with VIP values larger than 1.0
and p values less than 0.05 were selected, respectively.
Fold change was calculated as binary logarithm of aver-
age normalized peak area ratio between the two groups,
where the positive value means that the average mass
response of HUPM group is higher than LUPM group.
Identification of metabolites
The deconvoluted spectra by our data processing proto-
col were introduced to the NIST MS Search 2.0 soft-
ware for automatically searching compound information
from the NIST 08 library and the author-constructed
standard library. The searching results with match simi-
larity larger than 80% will be accepted as candidate
compounds. To obtain reliable results, a raw GC/MS
data file of QC sample was imported to the AMDIS
software http://chemdata.nist.gov/mass-spc/amdis/ for
automatically searching against an author-constructed
standard library including retention time and mass spec-
tra. The results obtained from the above two methods
were confirmed as reliable candidate compounds. The
retention times of reference standards were utilized to
confirm the candidate compounds. The Kovats retention
indexes of remaining candidate compounds were calcu-
lated and compared with a NIST RI database and avail-
able internet database such as NIST Chemistry
WebBook http://webbook.nist.gov/chemistry/.
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